Abstract:Objectives. Sjögren's syndrome (SS) may be complicated by some neurological manifestations, generally sensory polyneuropathy. Furthermore, involvement of cranial nerves was described as rare complications of SS. Methods. We reported 2 cases: the first one was a 40-year-old woman who developed neuritis of the left optic nerve as presenting symptom few years before the diagnosis of SS; the second was a 54-year-old woman who presented a paralysis of the right phrenic nerve 7 years after the SS onset. An exhaustiv… Show more
“… 4 However, NMO is now recognized as a spectrum disease that affects other regions of the CNS and includes more diverse clinical presentations because of the identification of a disease-specific autoantibody against aquaporin-4 (AQP4). 5 With increased numbers of emerging pSS patients with neuromyelitis optica spectrum disorder (NMOSD) cases reports, 6 – 8 studies of large Chinese populations have been rare. The aim of the present study was to assess the clinical characteristics, seroimmunological correlations, and risk factors for pSS with NMOSD in a Chinese cohort at a single center.…”
The aim of the present study was to analyze the clinical characteristics of primary Sjogren's syndrome (pSS) with neuromyelitis optica spectrum disorder (NMOSD). We retrospectively reviewed the medical records of 616 patients who were admitted to the Peking Union Medical College Hospital from 1985 to 2013. Of these patients, 43 developed NMOSD. The median duration of symptoms was 60 months and 72% of the patients experienced neurological complications onset in the pSS with NMOSD group. Twenty-one out of 43 patients had neuromyelitis optica (NMO), and 22 exhibited a limited form of NMO. Serum anti-aquaporin-4 (AQP4) antibody positivity was detected in 89.3% of the patients. A total of 60.5% of the patients (26 patients) complained of dry mouth, 72.1% were positive for objective xerostomia, 53.5% complained of dry eyes, and 74.4% had a positive ocular test. Biopsy of the minor salivary glands was performed in 33 patients, 28 of whom (84.8%) had a lymphocytic focus score of ≥1. Anti-Ro/SSA or anti-La/SSB antibodies were detected in 41 patients (95.3%). Compared with the pSS patients without NMOSD, the incidences of xerophthalmia, xerostomia, arthritis, interstitial lung disease, and renal tubular acidosis were significantly lower in the patients with NMOSD.NMOSD is a neurologic complication of pSS. The presence of anti-AQP4 antibody may be a predictor for pSS patients with NMOSD. Neurological manifestations are prominent in these patients. In clinical scenarios involving pSS or NMOSD, rheumatologists and neurologists should be aware of this association and perform the appropriate tests.
“… 4 However, NMO is now recognized as a spectrum disease that affects other regions of the CNS and includes more diverse clinical presentations because of the identification of a disease-specific autoantibody against aquaporin-4 (AQP4). 5 With increased numbers of emerging pSS patients with neuromyelitis optica spectrum disorder (NMOSD) cases reports, 6 – 8 studies of large Chinese populations have been rare. The aim of the present study was to assess the clinical characteristics, seroimmunological correlations, and risk factors for pSS with NMOSD in a Chinese cohort at a single center.…”
The aim of the present study was to analyze the clinical characteristics of primary Sjogren's syndrome (pSS) with neuromyelitis optica spectrum disorder (NMOSD). We retrospectively reviewed the medical records of 616 patients who were admitted to the Peking Union Medical College Hospital from 1985 to 2013. Of these patients, 43 developed NMOSD. The median duration of symptoms was 60 months and 72% of the patients experienced neurological complications onset in the pSS with NMOSD group. Twenty-one out of 43 patients had neuromyelitis optica (NMO), and 22 exhibited a limited form of NMO. Serum anti-aquaporin-4 (AQP4) antibody positivity was detected in 89.3% of the patients. A total of 60.5% of the patients (26 patients) complained of dry mouth, 72.1% were positive for objective xerostomia, 53.5% complained of dry eyes, and 74.4% had a positive ocular test. Biopsy of the minor salivary glands was performed in 33 patients, 28 of whom (84.8%) had a lymphocytic focus score of ≥1. Anti-Ro/SSA or anti-La/SSB antibodies were detected in 41 patients (95.3%). Compared with the pSS patients without NMOSD, the incidences of xerophthalmia, xerostomia, arthritis, interstitial lung disease, and renal tubular acidosis were significantly lower in the patients with NMOSD.NMOSD is a neurologic complication of pSS. The presence of anti-AQP4 antibody may be a predictor for pSS patients with NMOSD. Neurological manifestations are prominent in these patients. In clinical scenarios involving pSS or NMOSD, rheumatologists and neurologists should be aware of this association and perform the appropriate tests.
“…The involvement of cranial nerves is relatively rare [2]. In the published literature, isolated abducens nerve palsy has been reported in only 1 patient [3]. The current report presents a case of pSS with the involvement of cranial nerves.…”
Section: Introductionmentioning
confidence: 71%
“…Cranial neuropathies show symptoms depending on the cranial nerve involved. Among cranial nerves, the trigeminal nerve and optic nerves are the most commonly involved [3]. Visual changes can be quite profound in Sjögren's.…”
ÖzetSjögren sendromu (SS) ekzokrin bezlerin lenfositik infiltrasyonu ile karakterize otoimmun bir hastalıktır. Nörolojik tutulum hastaların yaklaşık dörttebirinde ortaya çıkmasına rağmen kranial sinir tutulumları çok daha nadiren görülmektedir. Burada kranial sinir tutulumu olan SS'lu bir vaka sunumu yapılmıştır.
Anahtar KelimelerSjögren Sendromu; Kranial Nöropati; Abdusens Sinir Felci Abstract Sjögren's syndrome (SS) is an autoimmune disorder characterized by lymphocytic infiltration of exocrine organs. Although neurological involvement occurs in approximately one quarter of patients, involvement of cranial nerves is a relatively rare occurrence. Here a rare case of cranial neuropathy related to SS is reported.
“…Anterior pituitary enlargement and palsy of cranial nerve VI in this patient initially raised the possibility of an inflammatory disorder of the pituitary or a pituitary adenoma. Indeed, hypophysitis, particularly granulomatous hypophysitis, can present as a sellar mass associated with cranial nerve palsies due to involvement of the adjacent cavernous sinus [ 29 ] as can occur with other inflammatory disorders of the pituitary including Sjögren's syndrome [ 30 , 31 ], sarcoidosis [ 32 ], Wegener's granulomatosis [ 33 , 34 ], tuberculosis [ 35 ], syphilis [ 36 , 37 ], and fungal infections [ 38 ]. Langerhans histiocytosis, germinoma, and lymphoma may also be associated with similar findings but often associated with central diabetes insipidus [ 39 – 41 ].…”
Carotid-cavernous fistulas (CCFs) are rare, pathologic communications of the carotid artery and the venous plexus of the cavernous sinus. They can develop spontaneously in certain at risk individuals or following traumatic head injury. Typical clinical manifestations include headache, proptosis, orbital pain, and diplopia. We report a case of bilateral carotid-cavernous fistulas associated with these symptoms and also with pituitary enlargement and hypopituitarism, which improved following surgical intervention. Arterialization of the cavernous sinus and elevated portal pressure may interfere with normal venous drainage and the conveyance of inhibiting and releasing hormones from the hypothalamus, resulting in pituitary enlargement and hypopituitarism. This condition should be considered in the differential diagnosis of hypopituitarism associated with anterior pituitary enlargement.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.